US 11,850,245 B2
Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
Michael T. Nordsiek, Wayne, PA (US); and Jefferson J. Gregory, Bristol, TN (US)
Assigned to Medicis Pharmaceutical Corporation, Bridgewater, NJ (US)
Filed by Medicis Pharmaceutical Corporation, Bridgewater, NJ (US)
Filed on Feb. 16, 2021, as Appl. No. 17/177,116.
Application 17/177,116 is a continuation of application No. 16/364,023, filed on Mar. 25, 2019, granted, now 10,918,635.
Application 16/364,023 is a continuation of application No. 15/990,590, filed on May 26, 2018, granted, now 10,238,645, issued on Mar. 26, 2019.
Application 15/990,590 is a continuation of application No. 14/796,296, filed on Jul. 10, 2015, granted, now 9,980,955, issued on May 29, 2018.
Application 14/796,296 is a continuation of application No. 14/091,965, filed on Nov. 27, 2013, granted, now 9,078,889, issued on Jul. 14, 2015.
Application 14/091,965 is a continuation of application No. 13/559,473, filed on Jul. 26, 2012, granted, now 8,642,616, issued on Feb. 4, 2014.
Application 13/559,473 is a continuation of application No. 12/771,076, filed on Apr. 30, 2010, abandoned.
Claims priority of provisional application 61/341,721, filed on Apr. 1, 2010.
Claims priority of provisional application 61/341,476, filed on Mar. 30, 2010.
Claims priority of provisional application 61/225,202, filed on Jul. 13, 2009.
Prior Publication US 2023/0020422 A1, Jan. 19, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 31/44 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 31/4745 (2006.01)
CPC A61K 31/4745 (2013.01) [A61K 9/0014 (2013.01); A61K 31/44 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 9/06 (2013.01)] 5 Claims
 
1. A method of treating external genital or perianal warts in a population of patients 12 years old or older in need thereof in a treatment period of eight weeks or less, the method comprising topically applying a 3.75% (w/w) imiquimod composition to the genital or perianal warts once a day for up to eight consecutive weeks;
wherein the treatment results in less than 10% incidents of severe erythema in the population.